OakChart

Cosmos Health Inc

COSMHealthcare·Medical Distribution·Greece·Nano·NASD·Nov 11 • 12:20 PM ET

0.2163+0.0185 (9.35%)
2026-11-11 18:20 CET
Market cap
19.91 USD m
Revenue, TTM
73.73 USD m
Net income, TTM
-24.39 USD m
Free cash flow, TTM
-11.71 USD m
EPS diluted, TTM
-0.65
P/E
-
Compare

Price

COSM against its 20, 50 and 200-day averages
2050200earnings
0.200.400.6065.2M130.4MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26COSMclose 0.2220-day 0.2850-day 0.31200-day 0.300.2252w low

71.9% under the 52-week high of 0.77 on 13 Nov 2025. 52-week low 0.16 on 30 Jun 2026. Last 15 sessions, 77.5% high to low

Profile

COSM
52-week range, 9% of the way up
0.160.77

Cosmos Health, Inc. is a pharmaceutical company, which engages in the importation, exportation, distribution, and sale of pharmaceutical products. It is also involved in the research and development of its business units, and acquisition of pharmaceutical companies. The firm offers over-the-counter drugs, branded and generic medicines, and dietary and vitamin supplements. The company was founded on July 21, 2009 and is headquartered in Thessaloniki, Greece.

Employees163
IPOJul 23, 2010
Beta4.48
ATR, 14d0.04
Rel volume0.74
Short float2.32%
Insider own23.88%
Inst own7.50%

Snapshot

6 groups

Valuation

Index-
Market Cap21.77M
Enterprise Value35.75M
Income-24.39M
Sales73.73M
Book/sh0.26
Cash/sh0.02
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees163
IPOJul 23, 2010

Ratios

P/E-
Forward P/E3.09
PEG-
P/S0.30
P/B0.84
P/C8.78
P/FCF-
EV/EBITDA-
EV/Sales0.48
Quick Ratio0.92
Current Ratio1.05
Debt/Eq0.80
LT Debt/Eq0.17
Option/ShortYes / Yes

Earnings

EPS (ttm)-0.65
EPS next Y0.07
EPS next Q-0.04
EPS this Y76.19%
EPS next Y146.67%
EPS next 5Y-
EPS past 3/5Y73.29% -
Sales past 3/5Y9.04% 3.33%
EPS Y/Y TTM34.05%
Sales Y/Y TTM33.82%
EPS Q/Q-3.25%
Sales Q/Q28.76%
EarningsAug 19 BMO
EPS/Sales Surpr.0.00% 1.75%

Ownership

Insider Own23.88%
Insider Trans10.10%
Inst Own7.50%
Inst Trans27.31%
ROA-39.56%
ROE-104.00%
ROIC-101.02%
Gross Margin8.39%
Oper. Margin-24.65%
Profit Margin-33.08%
SMA20-23.27%
SMA50-29.95%
SMA200-28.34%
Trades-

Technical

Shs Outstand80.67M
Shs Float76.60M
Short Float2.32%
Short Ratio0.59
Short Interest1.77M
52W High0.77 -71.91%
52W Low0.16 33.85%
Volatility18.40% 13.87%
ATR (14)0.04
RSI (14)38.31
Beta4.48
Rel Volume0.74
Avg Volume3.00M
Volume1,025,516

Performance

Perf Week-33.97%
Perf Month-43.51%
Perf Quarter4.75%
Perf Half Y-28.59%
Perf YTD-56.57%
Perf Year-70.21%
Perf 3Y-79.40%
Perf 5Y-99.78%
Perf 10Y-99.85%
Recom1.00
Target Price2.95
Prev Close0.20
Price0.22
Change %9.35%

Peers

Mkt cap
TickerCompanyMkt cap
YI111 Inc ADR14.79M
MEDSDataMEDS AI Inc4.27M
HKPDCellyan Biotechnology Co Ltd4.06M
PRGOPerrigo Company plc2.31B
HLNHaleon plc ADR39.84B
NATRNature's Sunshine Products Inc178.83M
HIMSHims & Hers Health Inc4.72B
NAIINatural Alternatives International Inc6.06M
USNAUsana Health Sciences Inc237.91M
LFVNLifevantage Corp61.13M

Insider trading

latest 14 of 21
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Siokas GrigoriosChief Executive OfficerJul 30 '26Buy0.20349,82570,00014,597,917Jul 31 11:52 AM
Siokas GrigoriosChief Executive OfficerJul 29 '26Buy0.18766,284140,00014,248,092Jul 30 11:09 AM
Terzis GeorgiosChief Financial OfficerJun 16 '26Buy0.25168,13542,0002,235,398Jun 17 09:15 AM
Siokas GrigoriosChief Executive OfficerJun 11 '26Buy0.21218,44745,00013,481,808Jun 12 01:22 PM
Siokas GrigoriosChief Executive OfficerJun 10 '26Buy0.23701,447160,00013,263,361Jun 12 06:20 AM
Siokas GrigoriosChief Executive OfficerFeb 12 '26Buy0.37388,532145,0008,861,914Feb 13 10:05 AM
Siokas GrigoriosChief Executive OfficerFeb 11 '26Buy0.41291,262120,0008,473,382Feb 12 02:20 PM
Siokas GrigoriosChief Executive OfficerJan 23 '26Buy0.5090,32545,0008,182,120Jan 26 11:48 AM
Siokas GrigoriosChief Executive OfficerJan 20 '26Buy0.50353,321175,0008,091,795Jan 21 10:11 AM
Siokas GrigoriosChief Executive OfficerJan 14 '26Buy0.45493,495220,0007,738,474Jan 15 09:40 AM
Siokas GrigoriosChief Executive OfficerJan 12 '26Buy0.50113,18557,0007,244,979Jan 13 10:00 AM
Siokas GrigoriosChief Executive OfficerJan 08 '26Buy0.52156,19081,0007,131,794Jan 09 11:43 AM
Siokas GrigoriosChief Executive OfficerJan 07 '26Buy0.52124,88065,0006,975,604Jan 08 10:41 AM
Siokas GrigoriosChief Executive OfficerJan 06 '26Buy0.54133,95372,0006,850,724Jan 07 01:01 PM

Held by

AUM
TickerCompanyAUM
VXFVanguard Extended Market Index ETFAUM: 30.47B

News

latest 14 of 101
  • Cosmos Health Provides U.S. E-Commerce Update for October 2026: Monthly Subscription Value Reaches $1.83 Million, Approximately $22 Million Annualized (ACCESSWIRE) +9.35%
  • Cosmos Health's CosmoFarm Begins Commissioning New Automated Order-Processing and Vehicle-Loading Infrastructure, Advancing Capacity That Could Support Over $120 Million in Annual Revenue (ACCESSWIRE) -11.51%
  • Cosmos Health's Amazon UK Business Surpasses $2 Million in TTM Sales, Up 90%, with a 23% Net Profit Margin; Expects Sales to Grow Approximately 72% to $3.9 Million Over the Next Twelve Months (ACCESSWIRE) +7.73%
  • Cosmos Health's U.S. Active Subscriptions Surpass 12,000, Up 92% in Two Weeks (ACCESSWIRE) +11.45%
  • Noble Capital Markets Initiates Equity Research Coverage on Cosmos Health with Outperform Rating and $1.40 Price Target (ACCESSWIRE) +5.51%
  • Loading…
  • Cosmos Health Expands E-Commerce and Subscription Business to Australia, New Zealand and the Broader Oceania Region, With Sales Already Underway (ACCESSWIRE) -9.87%
  • Cosmos Health CEO Greg Siokas Issues Letter to Shareholders Highlighting Record 2026 Revenue, U.S. Subscription Growth and Global Expansion (ACCESSWIRE)
  • Cosmos Health Provides Update on United States Business; Q4 2026 U.S. Revenue Expected to Reach $15 Million, with Gross Profit of $10.5 Million; Active U.S. Subscriptions Up 42% from 6,287 to 8,940 in Just Five Days (ACCESSWIRE)
  • Cosmos Health Reaches 6,287 Active U.S. Subscriptions, Substantially All Added Since Mid-September, with 60.5% of Online Checkout Orders Including a Subscription (ACCESSWIRE)
  • Cosmos Health Reports Record Single-Day Direct-to-Consumer Sales in the United States Above $92,000, with $902,000 in Sales Over the Past 30 Days (ACCESSWIRE) +9.53%
  • Cosmos Health Reports Record Preliminary Nine-Month Revenue of $54.3 Million, Up 19% Year Over Year; Delivers Record Q3 Revenue of $17.4 Million and Reaffirms 2026 Revenue Outlook of Over $90 Million (ACCESSWIRE)
  • Cosmos Health's Brands Reach More Than 40 Countries Across Europe, the Middle East, North America and Asia, Addressing Global Markets Estimated at Approximately $946 Billion (ACCESSWIRE) -10.19%
  • Cosmos Health's CosmoFarm Reaches Record Annualized Revenue Above $60 Million, Up 4.3x Under Cosmos Health Ownership, as Robotics and AI Build Capacity to Support Over $100 Million in Annualized Revenue (ACCESSWIRE) +13.67%

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q22026-08-19-0.100-0.100-0.17019.3218.991
2026Q12026-05-21-0.060-0.060-0.06017.9017.931
2025Q42026-04-15-0.330-0.040-0.31619.7018.821
2025Q32025-11-17-0.530--0.17517.11--
2024Q32024-11-14-0.450-0.110-0.45512.4114.001
2024Q22024-08-20-0.150--0.14513.21--
2023Q32023-11-29-0.270--0.26712.82--
2023Q22023-08-15---12.36--
2022Q32022-11-16---12.02--
2022Q22022-08-23---13.21--
2021Q12021-05-18---0.14011.62--
2020Q32020-11-17--0.06014.35--
2024Q4---0.090-0.404-14.501
2025Q1---0.030-0.031-15.501
2025Q2--0.010-0.098-17.481
2026Q3---0.040--17.342

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2023FY-2.150--2.15453.38-
2024FY--0.780-1.169-54.70
2025FY-0.630-0.340-65.3064.40
2026FY--0.150--85.40
2027FY-0.070--129.6
2028FY-0.140--160.77
2029FY-0.200--189

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q3S2026-10-2320117.3417.2817.40
2026Q3S2026-10-0610117.2817.2817.28
2026Q3S2026-08-1910120.8920.8920.89
2026Q3S2026-07-2310120.8920.8920.89
2026Q3S2026-05-2110121.6921.6921.69
2026Q3S2026-05-2010121.6921.6921.69
2026Q3S2026-04-1511026.2226.2226.22
2026Q3S2026-01-1210025.0525.0525.05
2026Q3E2026-10-23201-0.04-0.06-0.02
2026Q3E2026-10-06101-0.06-0.06-0.06
2026Q3E2026-08-19101-0.05-0.05-0.05
2026Q3E2026-07-23101-0.05-0.05-0.05
2026Q3E2026-06-291000.020.020.02
2026Q3E2026-05-211100.020.020.02

Estimate history

EPS, annual-12.25-17.023-6.2141.542-23.739-33.164-2.154-1.169-0.632-0.6522
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.145-0.455-0.404-0.031-0.098-0.175-0.316-0.06-0.102
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Sales, annual30.01337.08439.67655.40656.2450.34853.37754.42665.27273.73
Period201720182019202020212022202320242025TTM
Sales, quarterly13.20712.41114.22413.71314.74617.1119.70317.92818.986
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26
Shares, annual0.5070.5480.5140.5230.68610.5915.89623.60341.06780.671
Period201720182019202020212022202320242025MRQ
Shares, quarterly17.74823.2623.60327.19829.71831.86941.06749.78180.671
PeriodQ2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue73.7365.2754.4353.3850.3556.2455.4139.6837.08
Cost of Goods Sold Incl. D&A67.5558.7551.3649.6444.5848.3647.7436.4134.72
Gross Profit6.186.533.063.745.777.887.663.272.36
Selling, General and Administrative Excl. Other24.3523.0718.3125.5713.2412.414.953.523.59
Research and Development0.500.520.53------
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-18.17-16.54-15.25-21.83-7.47-4.532.71-0.26-1.23
Interest Expense3.702.621.010.873.973.582.801.736.81
Unusual Expense2.540.480.29-3.36-0.99-0.80-0.901.223.36
Net Income Before Taxes-24.39-19.14-16.18-18.54-13.06-7.851.20-3.12-9.04
Income Taxes0.000.000.000.000.780.110.380.180.02
Consolidated Net Income-24.39-19.14-16.18-18.54-13.83-7.960.82-3.30-9.06
Net Income From Continuing Operations-24.39-19.14-16.18-18.54-13.83-7.960.82-3.30-9.06
Net Income-24.39-19.14-22.38-25.78-63.95-15.590.82-3.30-9.06
EPS (Recurring)-0.38-0.62-1.16-2.35-33.52-24.590.35-4.60-12.61
EPS (Basic, Before Extraordinaries)-0.65-0.63-1.17-2.15-33.16-23.741.55-6.21-17.02
EPS (Diluted)-0.65-0.63-1.17-2.15-33.16-23.741.54-6.21-17.02
EBITDA-16.78-15.17-14.00-21.22-7.29-4.083.110.14-1.18
Non-Operating Income (Expense)0.020.500.370.80-2.60-0.540.380.092.35
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense2.001.260.990.58-4.31---
Price To Sales Ratio0.150.230.240.320.170.981.030.741.44
Gross Margin8.3910.005.637.0011.4614.0113.838.246.38
Operating Margin-24.65-25.34-28.02-40.90-14.84-8.064.90-0.64-3.31
Net Margin-33.08-29.33-41.12-48.31-127.01-27.731.48-8.31-24.43
Shares Outstanding80.6741.0723.6015.9010.590.690.520.510.55
Market Capitalization19.9119.9115.5618.9032.6232.62---

Income statement, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q12024Q42024Q3
Total Revenue18.9917.9319.7017.1114.7513.7114.2212.41
Cost of Goods Sold Incl. D&A17.8216.8917.9414.8913.9411.9813.5311.51
Gross Profit1.161.031.762.220.811.730.690.90
Selling, General and Administrative Excl. Other4.093.2213.014.043.462.568.833.14
Research and Development0.070.000.410.020.070.02--
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-2.93-2.18-11.24-1.82-2.65-0.83-8.14-2.24
Interest Expense1.000.811.010.870.550.190.320.18
Unusual Expense2.21-0.02-2.142.490.12-0.000.29-0.00
Net Income Before Taxes-6.09-2.81-10.15-5.35-2.83-0.82-9.54-2.18
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-6.09-2.81-10.15-5.35-2.83-0.82-9.54-2.18
Net Income From Continuing Operations-6.09-2.81-10.15-5.35-2.83-0.82-9.54-2.18
Net Income-6.09-2.81-10.15-5.35-2.83-0.82-9.54-8.38
EPS (Recurring)-0.08-0.06-0.36-0.12-0.10-0.03-0.40-0.45
EPS (Basic, Before Extraordinaries)-0.10-0.06-0.32-0.17-0.10-0.03-0.40-0.45
EPS (Diluted)-0.10-0.06-0.32-0.17-0.10-0.03-0.40-0.45
EBITDA-2.58-1.84-10.93-1.44-2.29-0.51-7.83-1.94
Non-Operating Income (Expense)0.050.17-0.03-0.180.490.20-0.260.24
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense0.530.460.730.290.290.250.270.26
Price To Sales Ratio0.150.210.240.570.220.21--
Gross Margin6.125.768.9413.005.4912.614.867.27
Operating Margin-15.41-12.18-57.07-10.63-17.94-6.08-57.24-18.05
Net Margin-32.06-15.65-51.49-31.28-19.18-5.97-67.09-67.50
Shares Outstanding80.6749.7841.0731.8729.7227.2023.6023.26
Market Capitalization19.9111.8718.5734.4312.2810.1415.5615.55

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments3.510.343.8520.760.290.850.283.580.78
Short Term Receivables23.0116.4121.9026.4830.1426.919.274.941.43
Inventories5.784.364.793.453.153.293.473.203.09
Other Current Assets6.094.356.075.357.309.728.156.624.21
Total Current Assets38.3925.4636.6156.0440.8840.7721.1818.359.51
Net Property, Plant & Equipment11.1810.4011.622.931.881.761.731.430.11
Total Investments and Advances0.000.000.170.160.000.000.000.000.00
Long-Term Note Receivable3.155.777.0512.394.41----
Intangible Assets8.987.767.680.710.490.230.260.300.04
Deferred Tax Assets0.24-0.280.336.943.26-0.00-
Other Assets3.784.922.890.550.920.910.700.621.01
Total Assets65.7254.3166.3073.1155.5146.9323.8820.6910.68
Short Term Debt Incl. Current Port. of LT Debt15.049.768.548.3613.6020.9518.8515.0210.18
Accounts Payable16.6311.8911.9611.7212.7311.988.806.072.17
Income Tax Payable--0.000.131.320.760.180.001.36
Other Current Liabilities6.614.113.831.542.281.100.411.180.00
Total Current Liabilities38.2725.7624.3221.7529.9334.7928.2422.2713.70
Long Term Debt6.232.063.895.6515.1213.111.991.550.00
Provision for Risks Charges0.380.380.000.000.000.000.000.000.00
Deferred Tax Liabilities0.24-0.280.336.093.09---
Other Liabilities2.171.581.761.360.000.110.110.180.00
Total Liabilities47.3029.7830.2529.0851.1451.0930.3424.0113.70
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity18.4224.5336.0444.034.38-4.16-6.46-3.32-3.03
Total Shareholders Equity18.4224.5336.0444.034.38-4.16-6.46-3.32-3.03
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity18.4224.5336.0444.034.38-4.16-6.46-3.32-3.03
Total Liabilities & Stockholders Equity65.7254.3166.3073.1155.5146.9323.8820.6910.68
Book Value Per Share0.451.042.274.166.38-7.96-12.56-6.05-5.98
Tangible Book Value Per Share0.230.711.784.095.66-8.40-13.07-6.59-6.06
Full-Time Employees1631491231029585716741
Price to Book Ratio0.770.440.411.381.38----
Return on Assets-31.90-26.84-26.60-21.50-15.542.32-14.80-57.77-90.03
Return on Equity-89.13-53.43-46.31-57.13-7,289.22----
Return on Invested Capital-77.67-60.85-46.44-27.84-40.839.18---
Quick Ratio0.850.821.312.421.261.080.630.680.47
Current Ratio1.000.991.512.581.371.170.750.820.69

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-24.39-19.14-16.18-18.54-13.83-7.960.82-3.30-9.06
Depreciation1.391.371.250.610.190.450.400.390.04
Other Funds (Non Cash)11.738.256.689.393.497.43-0.851.736.79
Funds from Operations-11.27-9.50-8.27-8.46-9.37-0.800.37-1.18-2.22
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-0.34-0.780.16-7.90-8.69-6.30-11.87-3.610.67
Income Taxes Payable--0.00-0.13-1.110.620.580.180.06
Cash from Operating Activities-11.61-10.28-8.11-16.35-18.07-7.10-11.50-4.79-1.56
Capital Expenditures-3.21-2.15-1.27-7.50-0.38-0.89-0.12-0.67-0.50
Net Assets From Acquisitions0.000.000.00-6.900.000.000.000.00-
Sale of Fixed Assets and Businesses0.000.000.000.000.010.000.000.000.31
Purchase or Sale of Investments0.000.000.000.00-0.000.000.001.260.00
Purchase of Investments0.000.000.000.00-0.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.000.001.260.00
Other Uses0.000.000.00-0.170.000.000.000.000.00
Other Sources0.540.140.470.810.350.060.000.000.00
Cash from Investing Activities-2.67-2.01-0.80-13.76-0.02-0.83-0.120.59-0.20
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock7.855.424.8913.4352.10-0.13-0.20-0.85-0.08
Repurchase of Common Pref Stock-0.510.000.000.000.00-0.38-0.20-0.85-0.08
Sale of Common Pref Stock8.365.424.8913.4352.100.250.000.000.00
Proceedsfrom Stock Options8.365.420.659.9041.280.250.000.000.00
Issuance or Reduction of Debt, Net7.9610.470.55-0.02-13.867.3912.664.432.07
Change in Long Term Debt8.749.26-0.26-0.58-12.09-0.09-0.09-0.071.55
Issuance of Long Term Debt10.3811.160.871.060.490.000.000.001.55
Reduction of Long Term Debt-1.64-1.89-1.13-1.64-12.58-0.09-0.09-0.070.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.000.000.000.00
Cash from Financing Activities15.8015.895.4413.4138.247.2712.463.591.99
Exchange Rate Effect0.27-0.45-0.05-0.210.310.31-0.25-0.21-0.16
Net Change in Cash1.793.14-3.52-16.9220.46-0.340.59-0.830.08
Free Cash Flow-11.71-10.33-8.53-17.67-18.14-7.68-11.62-5.46-2.06
Preferred Dividends (Cash Flow)-0.00----0.000.000.00
Deferred Taxes & Investment Tax Credit-0.02-0.010.080.78-0.710.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Cash & Short Term Investments2.482.193.514.670.690.77
Short Term Receivables22.1521.4623.0122.0018.9117.64
Inventories4.525.655.785.685.114.74
Other Current Assets7.527.596.095.765.854.70
Total Current Assets36.6736.8938.3938.1030.5627.84
Net Property, Plant & Equipment10.7810.9511.1811.3211.5010.70
Total Investments and Advances0.000.000.001.000.000.00
Intangible Assets8.639.298.987.968.237.80
Deferred Tax Assets--0.24---
Other Assets2.402.113.785.275.295.04
Total Assets61.4662.3765.7269.4961.8457.19
Short Term Debt Incl. Current Port. of LT Debt12.9911.8915.0418.0613.1410.29
Accounts Payable14.5014.8216.6314.6813.4312.29
Other Current Liabilities7.367.376.615.804.594.01
Total Current Liabilities34.8434.0838.2738.5331.1726.59
Long Term Debt3.476.596.236.142.512.56
Provision for Risks Charges0.000.380.380.430.000.00
Deferred Tax Liabilities--0.24---
Other Liabilities2.481.502.171.251.932.10
Total Liabilities40.7942.5447.3046.3635.6031.24
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity20.6719.8318.4223.1326.2325.95
Total Shareholders Equity20.6719.8318.4223.1326.2325.95
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity20.6719.8318.4223.1326.2325.95
Total Liabilities & Stockholders Equity61.4662.3765.7269.4961.8457.19
Book Value Per Share0.260.400.450.730.880.95
Tangible Book Value Per Share0.150.210.230.480.610.67
Full-Time Employees--163---
Price to Book Ratio0.770.440.691.260.440.29
Return on Assets-39.56-35.35-31.90-27.67-25.06-
Return on Equity-104.00-92.33-89.13-63.82-52.69-
Return on Invested Capital-25.21-10.62-41.16-18.29-9.84-2.87
Quick Ratio0.920.920.850.840.820.87
Current Ratio1.051.081.000.990.981.05

Cash flow, quarterly

Currency USD, millions
Metric2026Q22026Q12025Q42025Q32025Q22025Q1
Net Income-6.09-2.81-10.15-5.35-2.83-0.82
Depreciation0.350.350.320.380.350.32
Other Funds (Non Cash)3.521.325.041.850.770.60
Funds from Operations-2.22-1.14-4.79-3.12-1.690.11
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital0.430.020.06-0.850.30-0.29
Cash from Operating Activities-1.79-1.12-4.73-3.97-1.39-0.19
Capital Expenditures-0.08-1.11-2.01-0.01-0.12-0.01
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.000.001.00-1.000.000.00
Purchase of Investments0.000.001.00-1.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.200.40-0.060.000.190.01
Cash from Investing Activities0.11-0.71-1.07-1.010.07-0.01
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.601.834.401.020.000.00
Repurchase of Common Pref Stock-0.510.000.000.000.000.00
Sale of Common Pref Stock1.111.834.401.020.000.00
Proceedsfrom Stock Options1.111.834.401.020.000.00
Issuance or Reduction of Debt, Net1.27-1.430.447.691.790.56
Change in Long Term Debt0.28-0.26-1.109.81-0.000.55
Issuance of Long Term Debt0.520.00-0.7910.650.550.74
Reduction of Long Term Debt-0.23-0.26-0.31-0.84-0.56-0.19
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities1.860.404.838.711.790.56
Exchange Rate Effect0.100.13-0.210.25-0.550.06
Net Change in Cash0.29-1.30-1.173.98-0.090.43
Free Cash Flow-1.86-1.13-4.74-3.98-1.41-0.20

Revenue breakdown

Greece2024: 54.43M 2025: 65.27M
Nutraceuticals and Pharmaceuticals2024: 1.97M 2025: 4.26M
Other2025: 1.23K
Pharma manufacturing2024: 865.37K 2025: 1.69M
Wholesale2024: 51.59M 2025: 59.32M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-302.32%1.8M76.6M3.16M
2026-10-152.98%2.3M76.6M3.55M
2026-09-303.25%2.6M78.8M5.93M
2026-09-153.83%3.0M78.8M7.71M
2026-08-3114.61%4.1M27.9M9.80M
2026-08-145.82%3.8M65.2M9.63M
2026-07-3123.73%4.1M17.2M9.33M
2026-07-1527.73%5.6M20.2M8.88M
2026-06-3011.38%4.7M41.7M6.10M
2026-06-155.92%2.3M39.6M3.53M
2026-05-292.68%0.9M33.2M969.30K
2026-05-152.94%1.0M33.2M917.48K
2026-04-302.21%0.6M28.2M888.19K
2026-04-151.59%0.5M32.0M802.62K
2026-03-310.68%0.2M23.6M811.57K
2026-03-130.63%0.1M23.6M821.97K
2026-02-271.42%0.3M23.6M888.30K
2026-02-130.51%0.1M23.6M839.68K
2026-01-300.43%0.1M24.4M771.13K
2026-01-150.22%0.1M24.5M690.48K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call0.500.000.050.037.7941,2060.000.469-0.0050.000
call1.000.000.600.039.8991950.000.428-0.0070.000
call1.500.001.000.0510.97742.000.000.413-0.0070.000
call2.000.001.000.0011.6930.000.000.404-0.0080.000
call2.500.000.050.0012.2250.000.000.398-0.0080.000
call5.000.000.050.0513.7694.000.000.383-0.0090.000
call7.500.000.050.0514.6091590.000.376-0.0090.000
put0.500.250.350.418.55187.001.00-0.540-0.0060.000
put1.000.450.850.9011.22011.000.00-0.593-0.0070.000
put1.500.601.351.3511.99218.000.00-0.599-0.0080.000
put2.001.101.851.8512.7859.000.00-0.608-0.0080.000
put2.501.602.352.3013.39514.000.00-0.614-0.0080.000
put5.004.204.904.8519.4056.000.00-0.641-0.0090.000
put7.506.707.407.3520.4859.000.00-0.649-0.0100.000

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-108-K/A2026-11-09SEC
2026-11-108-KCurrent report2026-11-09SEC
2026-10-30SCHEDULE 13G/ASEC
2026-10-29SCHEDULE 13GSEC
2026-10-228-KCurrent report2026-10-19SEC
2026-10-16SCHEDULE 13G/ASEC
2026-10-098-KCurrent report2026-10-07SEC
2026-08-208-KCurrent report2026-08-19SEC
2026-08-1810-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-14NT 10-Q2026-06-30SEC
2026-07-314Statement of changes in beneficial ownership of securities2026-07-30SEC
2026-07-304Statement of changes in beneficial ownership of securities2026-07-29SEC
2026-07-304Statement of changes in beneficial ownership of securities2026-07-29SEC
2026-07-22RWRegistration Withdrawal RequestSEC
2026-07-17S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-07-168-KCurrent report2026-07-15SEC
2026-07-068-KCurrent report2026-06-30SEC
2026-06-174Statement of changes in beneficial ownership of securities2026-06-16SEC
2026-06-124Statement of changes in beneficial ownership of securities2026-06-11SEC
2026-06-124Statement of changes in beneficial ownership of securities2026-06-10SEC
2026-06-114Statement of changes in beneficial ownership of securities2026-05-19SEC
2026-06-114Statement of changes in beneficial ownership of securities2026-05-19SEC
2026-06-114Statement of changes in beneficial ownership of securities2026-05-19SEC
2026-06-114Statement of changes in beneficial ownership of securities2026-05-19SEC
2026-06-114Statement of changes in beneficial ownership of securities2026-05-19SEC
2026-06-114Statement of changes in beneficial ownership of securities2026-05-19SEC
2026-06-114Statement of changes in beneficial ownership of securities2026-05-19SEC
2026-06-115Annual statement of changes in beneficial ownership of securities2025-12-31SEC
2026-06-115Annual statement of changes in beneficial ownership of securities2025-12-31SEC
2026-06-115Annual statement of changes in beneficial ownership of securities2025-12-31SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-07210.00K200
2026-06247.00K300
2026-050000
2026-040000
2026-030000
2026-02265.00K200
2026-01715.00K700
2025-12113.00K200
2025-11194.00K500

Institutional holders

Manager% owned
VANGUARD FIDUCIARY TRUST CO0.54%
JANE STREET GROUP, LLC0.47%
BlackRock, Inc.0.43%
GEODE CAPITAL MANAGEMENT, LLC0.40%
UBS Group AG0.35%
VANGUARD CAPITAL MANAGEMENT LLC0.28%
CITIGROUP INC0.11%
NORTHERN TRUST CORP0.09%
STATE STREET CORP0.07%
Sassicaia Capital Advisers LLC0.06%

Funds

Fund% owned
VANGUARD EXTENDED MARKET INDEX FUND0.28%
Fidelity Extended Market Index Fund0.27%
Fidelity Series Total Market Index Fund0.03%
Fidelity Total Market Index Fund0.02%
Fidelity Nasdaq Composite Index Fund0.00%

OakChart. COSM. Cached 15 minutes.

Some panels did not load: ratings.